Moreover, we observed that genetic and pharmacological inhibition of SETD8, by using a substrate-competitive inhibitor, UNC0379 [23], impaired NB growth in in vitro assays and in preclinical in vivo models of NB. This evidence concerns the gene KMT5A and neuroblastoma.